- Trial phase
- Approved
- Time to market
- Already launched. FDA approved September 2026; UK MHRA authorized October 2026. Commercial availability in the U.S. is underway.
- Why 3/10
- Onswik is already FDA-approved and commercializing (September 2026), with no pending regulatory decision or pivotal readout in the next ~12 months. While it is a meaningful new product, it is one asset within Eli Lilly's large, diversified portfolio and does not represent a make-or-break binary catalyst for the stock.
With the FDA approval binary behind it, watch for commercial uptake metrics (prescription trends, formulary wins, payer coverage) in Lilly's quarterly reports, and for potential EU approval timing or a type 1 diabetes trial update. Onswik's market-share battle with Novo Nordisk's Awiqli is the key competitive dynamic to track over the next 12-18 months.
Price Chart
Executive Summary
Onswik (insulin efsitora alfa-gobe) is Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes, approved by the FDA on September 23-24, 2026. It reduces required insulin injections from up to 365 per year to 52, addressing a major adherence barrier. Phase 3 QWINT trials (>3,400 patients) showed non-inferior blood sugar (A1C) reduction versus daily basal insulins glargine and degludec. Onswik is the second once-weekly insulin approved in the U.S. after Novo Nordisk's Awiqli (approved March 2026, launched August 2026). The UK's MHRA authorized Onswik on October 13, 2026, backed by a positive NICE recommendation. For Lilly, a massive diversified pharma, Onswik is a meaningful portfolio addition but not a single-asset binary; the stock is driven primarily by GLP-1 drugs like Mounjaro/Zepbound.
How It Works
A long-acting insulin analog that mimics the body's natural basal (background) insulin. It is designed to be injected just once per week rather than once or twice daily, maintaining steady blood-sugar control between meals and overnight. It works by activating insulin receptors to help cells absorb glucose from the bloodstream.
Trial Status
The QWINT Phase 3 program (QWINT-1 through QWINT-4) enrolled over 3,400 adults with type 2 diabetes across four global registration trials. All studies met their primary endpoint: non-inferior A1C reduction versus once-daily basal insulins (glargine or degludec). In QWINT-1, efsitora reduced A1C by 1.31% vs 1.27% for glargine at 52 weeks. Topline results were presented at the ADA 85th Scientific Sessions in 2025 and published in peer-reviewed journals including The Lancet and NEJM.
The Two-Sided Case
Upcoming Catalysts
- First full-quarter commercial sales data (likely in LLY Q4 2026 earnings, early 2027)
- Potential European Medicines Agency (EMA) decision on marketing authorization
- Any update on type 1 diabetes development following safety signals in QWINT-5
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ELI LILLY & Co 8-K LLY ·Originating report